Brokerages Set Compass Therapeutics, Inc. (NASDAQ:CMPX) Price Target at $11.77

Compass Therapeutics, Inc. (NASDAQ:CMPX) has earned an average rating of “Moderate Buy” from the sixteen analysts that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, thirteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $11.7692.

A number of research analysts recently weighed in on CMPX shares. Citizens Jmp reissued a “market outperform” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a research note on Tuesday, April 28th. Citigroup reaffirmed a “market outperform” rating on shares of Compass Therapeutics in a research report on Thursday, June 4th. Canaccord Genuity Group lowered their price target on Compass Therapeutics from $13.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday, April 28th. D. Boral Capital reissued a “buy” rating and issued a $30.00 price target on shares of Compass Therapeutics in a research report on Monday, April 27th. Finally, Stifel Nicolaus set a $6.00 price objective on shares of Compass Therapeutics in a research note on Monday, June 1st.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Seven Fleet Capital Management LP acquired a new position in Compass Therapeutics during the 2nd quarter worth $510,415,000. Artia Global Partners LP acquired a new stake in shares of Compass Therapeutics in the second quarter valued at about $839,000. Bank of America Corp DE acquired a new stake in shares of Compass Therapeutics in the second quarter valued at about $1,242,000. Jupiter Topco LLC bought a new stake in Compass Therapeutics during the 2nd quarter valued at approximately $121,000. Finally, ADAR1 Capital Management LLC acquired a new stake in Compass Therapeutics in the 2nd quarter valued at approximately $267,000. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Price Performance

Compass Therapeutics stock opened at $2.31 on Friday. Compass Therapeutics has a one year low of $1.61 and a one year high of $6.88. The company’s fifty day moving average price is $2.11 and its two-hundred day moving average price is $3.69. The company has a market capitalization of $416.01 million, a price-to-earnings ratio of -5.77 and a beta of 0.92.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). As a group, sell-side analysts anticipate that Compass Therapeutics will post -0.46 earnings per share for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.